Last reviewed · How we verify
Placebo for Spiriva Handihaler®
Placebo for Spiriva Handihaler® is a Small molecule drug developed by Mylan Inc.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD).
This is a placebo, meaning it has no active therapeutic effect.
This is a placebo, meaning it has no active therapeutic effect. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Placebo for Spiriva Handihaler® |
|---|---|
| Sponsor | Mylan Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological systems or receptors. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- No adverse events
Key clinical trials
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD (PHASE3)
- Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness (PHASE3)
- AMPLIFY - D6571C00001 Duaklir USA Phase III Study (PHASE3)
- Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2 (PHASE4)
- Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1 (PHASE4)
- Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study (PHASE2)
- PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Spiriva Handihaler® CI brief — competitive landscape report
- Placebo for Spiriva Handihaler® updates RSS · CI watch RSS
- Mylan Inc. portfolio CI
Frequently asked questions about Placebo for Spiriva Handihaler®
What is Placebo for Spiriva Handihaler®?
How does Placebo for Spiriva Handihaler® work?
What is Placebo for Spiriva Handihaler® used for?
Who makes Placebo for Spiriva Handihaler®?
What development phase is Placebo for Spiriva Handihaler® in?
What are the side effects of Placebo for Spiriva Handihaler®?
Related
- Manufacturer: Mylan Inc. — full pipeline
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Compare: Placebo for Spiriva Handihaler® vs similar drugs
- Pricing: Placebo for Spiriva Handihaler® cost, discount & access